146 related articles for article (PubMed ID: 36835818)
21. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
22. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
24. Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study.
Moey MYY; Liles DK; Carabello BA
Cardiooncology; 2019; 5():9. PubMed ID: 32154015
[TBL] [Abstract][Full Text] [Related]
25. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine.
Samuel Y; Babu A; Karagkouni F; Ismail A; Choi S; Boussios S
Curr Issues Mol Biol; 2023 Oct; 45(10):8337-8358. PubMed ID: 37886969
[TBL] [Abstract][Full Text] [Related]
26. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
27. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
28. Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.
De Sanctis R; Giordano L; D'Antonio F; Agostinetto E; Marinello A; Guiducci D; Masci G; Losurdo A; Zuradelli M; Torrisi R; Santoro A
Breast; 2021 Jun; 57():80-85. PubMed ID: 33780903
[TBL] [Abstract][Full Text] [Related]
29. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem G; Lancellotti P; Kim SB
Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
[TBL] [Abstract][Full Text] [Related]
30. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
31. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
32. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.
Lancellotti P; Galderisi M; Donal E; Edvardsen T; Popescu BA; Farmakis D; Filippatos G; Habib G; Lestuzzi C; Santoro C; Moonen M; Jerusalem G; Andarala M; Anker SD;
ESC Heart Fail; 2017 Aug; 4(3):312-318. PubMed ID: 28772051
[TBL] [Abstract][Full Text] [Related]
33. Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.
Kosalka P; Johnson C; Turek M; Sulpher J; Law A; Botros J; Dent S; Aseyev O
Curr Oncol; 2019 Jun; 26(3):e314-e321. PubMed ID: 31285674
[TBL] [Abstract][Full Text] [Related]
34. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
35. Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital.
Chen CB; Dalsania RK; Hamad EA
Cardiooncology; 2021 Jan; 7(1):3. PubMed ID: 33494840
[TBL] [Abstract][Full Text] [Related]
36. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
37. An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.
Yu L; Allen R; Jia L; Sun T; Isakoff SJ; Scherrer-Crosbie M; Kehlmann AM; Zheng H; Ly A; Walmsley CS; Hesler K; Varasteh AN; Pinto CJ; McLoughlin DE; Wu W; Wang X
Front Oncol; 2022; 12():809715. PubMed ID: 35592673
[TBL] [Abstract][Full Text] [Related]
38. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
[TBL] [Abstract][Full Text] [Related]
39. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
40. Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy.
Huang P; Huang JH; Zheng YB; Cao WM; Shao XY; Chen JQ; Huang Y; Li GL; Sharma K; Zhou HH; Wang XJ; Jin HC; Chen ZH
Front Pharmacol; 2022; 13():883600. PubMed ID: 35991878
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
